NasdaqCM:VKTXBiotechs
Does Viking’s Phase 3 Obesity Push and Unused Buyback Program Reshape The Bull Case For VKTX?
Viking Therapeutics reported a full-year 2025 net loss of US$359.64 million, with basic loss per share widening to US$3.19 from US$1.01 a year earlier, and disclosed that it executed no share repurchases under its previously announced buyback program.
At the same time, the company is pushing its obesity pipeline forward, including phase 3 development of injectable VK2735 and planned late-stage trials for its oral counterpart and a dual amylin–calcitonin receptor agonist.
We’ll now examine...